全文获取类型
收费全文 | 1658篇 |
免费 | 88篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 42篇 |
妇产科学 | 15篇 |
基础医学 | 136篇 |
口腔科学 | 17篇 |
临床医学 | 130篇 |
内科学 | 580篇 |
皮肤病学 | 14篇 |
神经病学 | 128篇 |
特种医学 | 287篇 |
外科学 | 128篇 |
综合类 | 17篇 |
预防医学 | 38篇 |
眼科学 | 4篇 |
药学 | 81篇 |
1篇 | |
中国医学 | 8篇 |
肿瘤学 | 129篇 |
出版年
2022年 | 5篇 |
2021年 | 12篇 |
2020年 | 11篇 |
2019年 | 17篇 |
2018年 | 16篇 |
2017年 | 8篇 |
2016年 | 13篇 |
2015年 | 23篇 |
2014年 | 21篇 |
2013年 | 25篇 |
2012年 | 53篇 |
2011年 | 75篇 |
2010年 | 49篇 |
2009年 | 44篇 |
2008年 | 55篇 |
2007年 | 76篇 |
2006年 | 58篇 |
2005年 | 67篇 |
2004年 | 65篇 |
2003年 | 50篇 |
2002年 | 54篇 |
2001年 | 52篇 |
2000年 | 60篇 |
1999年 | 54篇 |
1998年 | 50篇 |
1997年 | 49篇 |
1996年 | 44篇 |
1995年 | 60篇 |
1994年 | 47篇 |
1993年 | 42篇 |
1992年 | 19篇 |
1991年 | 21篇 |
1990年 | 31篇 |
1989年 | 66篇 |
1988年 | 33篇 |
1987年 | 39篇 |
1986年 | 48篇 |
1985年 | 29篇 |
1984年 | 23篇 |
1983年 | 19篇 |
1982年 | 15篇 |
1981年 | 19篇 |
1980年 | 18篇 |
1979年 | 12篇 |
1978年 | 25篇 |
1977年 | 17篇 |
1976年 | 13篇 |
1975年 | 13篇 |
1971年 | 10篇 |
1957年 | 6篇 |
排序方式: 共有1758条查询结果,搜索用时 15 毫秒
1.
J R Voelker D Cartwright-Brown S Anderson J Leinfelder D A Sica J P Kokko D C Brater 《Kidney international》1987,32(4):572-578
Furosemide and bumetanide share a number of characteristics including reduced natriuretic effects in azotemic patients. It has been presumed that this condition affects each drug equally. Previous studies, however, suggest dissimilar pathways of delivery to their sites of action. Though not rigorously tested, this potential disparity might cause them to differ when used in azotemia. We, therefore, assessed the pharmacokinetic and pharmacodynamic characteristics of intravenously administered furosemide and bumetanide in ten adult patients with stable, chronic renal insufficiency (mean creatinine clearance = 14.1 +/- 2.0 ml/min/1.73 m2) in a randomized, cross-over study during controlled sodium intake. Our goals were to assess differences in diuretic effectiveness and in so doing to determine the dose required to produce a maximal response. The mean diuretic doses of 172 and 4.3 mg for furosemide and bumetanide, respectively (ratio = 40:1) were sufficient to produce a maximum response. Despite similarities in maximal fractional excretion of sodium (18.2 +/- 2.6% with furosemide vs. 19.4 +/- 4.5% with bumetanide, P = 0.687) demonstrating an equal tubular responsiveness to both drugs, overall response as quantified by cumulative natriuresis in the initial eight hour period was 52% greater with furosemide (108 +/- 17 vs. 71 +/- 7 mEq; P = 0.042). The difference in total excreted sodium was accounted for by a preserved nonrenal clearance of bumetanide (113 +/- 12 compared to 53 +/- 5 ml/min for furosemide, P = 0.001) which resulted in relatively less bumetanide in serum available to be delivered into the urine.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
2.
C. A. Mangone E. M. Castaño E. Levy G. Abiusi T. Wisniewski M. R. Marques E. Faccio P. B. Gorelick B. Frangione and R. E. P. Sica 《Acta neurologica Scandinavica》1995,91(1):6-13
We report the clinical, SPET, immunohistochemical and DNA features of an early-onset familial Alzheimer's disease (FAD) in an Argentine pedigree of South American indian ethnic background. Pedigree spans 5 generations comprising more than 110 biological relatives. Clinical data supported the diagnosis of early onset FAD (mean age at onset 38.9 years) in 10 family members, including 3 with pathological confirmation (mean age at death 48.5). The pattern of transmission suggested autosomal dominant inheritance. Prominent features were mood changes, early language impairment, myoclonus, seizures and cerebellar signs. SPET displayed bilateral frontal, temporo-parietal and cerebellar hypoperfusion in early stages and in an asymptomatic member at risk, suggesting that SPET may have predictive value in this family. Immunohistochemistry showed β amyloid deposits within neuritic plaques and vessel walls and no anti-PrP immunoreactivity. DNA analysis showed no abnormalities in the β amyloid precursor protein gene. The identification of additional genetic defects in well characterized independent FAD pedigrees will contribute to the understanding of the pathogenesis of Alzheimer's disease. 相似文献
3.
4.
RAFAEL BEYAR M.D. D.Sc. ARIEL ROGUIN M.D. JAAP HAMBURGER M.D. RE SAAIMAN M.D. ANTONIO L. BARTORELLI M.D. CARLO DiMARIO M.D. ANTONIO COLOMBO M.D. CHRISTIAN W. HAMM M.D. CHRISTOPHER J. WHITE M.D. J. MARCO M.D. PATRICK W. SERRUYS M.D. Ph.D. 《Journal of interventional cardiology》1997,10(4):277-286
The beStent is a new stainless steel, balloon-expandable mesh stent which has a unique serpentine design. Rotation of the unique low stress junctions upon expansion leads to orthogonal locking of the wires, maximizing radial strength and assuring zero shortening. The stent has delineating gold markers which assure precise positioning. We aim to present the initial acute results in a pilot registry for stent evaluation. Two hundred eighty-four stents were used in a total of 217 patients (age 57.9 ± 3.10 years; 178 males; 39 females) in seven centers, for variable indications. Stents of 15-, 25-, and 35-mm length were used. The arteries treated were the left anterior descending (n = 112, 42%), circumflex (n = 54, 20.2%), right coronary (n = 95, 35.5%), left main (n = 1, 0.4%), and vein graft (n = 5, 1.9%). Lesion types were: A in 42 patients (16.5%); B1 in 53 patients (20.7%); B2 in 81 patients (31.8%); and C in 79 patients (31%). One hundred fifty-nine patients required one stent, 40 patients required two stents, and 18 patients required three or more stents. Anticoagulation protocol included procedural heparin with aspirin with/without ticlopidine. Smooth angiographie results were obtained in all cases with no plaque herniation. Acute angiographic success was obtained in 97% of the patients, and acute clinical success in 95% of the patients. Complications within 30 days were: 3 deaths (1.4%) (2 noncardiac); 2 (0.9%) myocardial infarctions; and 2 (0.9%) stent thromboses. Therefore, the beStent is useful in treatment of complex lesions of variable length and complexity, providing excellent acute results with a low complication rate, in spite of unfavorable basic clinical and angiographie characteristics. 相似文献
5.
D Rudy D A Sica T Comstock J Davis J Savory A C Schoolwerth 《The International journal of artificial organs》1991,14(10):625-629
The influence of a sodium citrate/citric acid mixture on the gastrointestinal (GI) absorption of aluminum (Al) from an Al(OH)3 preparation was evaluated in six stable maintenance hemodialysis patients. Plasma Al concentrations were determined serially after each of the following treatment sequences (I) Al(OH)3; (II) Al(OH)3 + sodium citrate/citric acid; (III) sodium citrate/citric acid; (IV) Al(OH)3 + NaHCO3. AUC0-8 for plasma Al from 0 to 8 hours was significantly greater (p less than 0.05) for Al(OH)3 + sodium citrate/citric acid (73 +/- 23 micrograms.hr/l; mean +/- SEM) than Al(OH)3 (16 +/- 30 micrograms.hr/l); sodium citrate/citric acid (-27 +/- 14 micrograms.hr/l); or Al(OH)3 + NaHCO3 (6 +/- 22 micrograms.hr/l). The 24 hour Al level remained above baseline (p less than 0.03) following Al(OH)3 + sodium citrate/citric acid (31 +/- 12 (pre) vs 54 +/- 14 micrograms/l (post), in contradistinction to study limb: l (34 +/- 14 vs 30 +/- 12 micrograms/l); III (79 +/- 40 vs 65 +/- 35 micrograms/l); and IV (71 +/- 37 vs 66 +/- 42 micrograms/l). We conclude that the GI absorption of Al from Al(OH)3 is enhanced by citrate in patients undergoing hemodialysis and that elevations of plasma Al persist longer. The concomitant administration of citrate and Al-containing phosphate (PO4) binders should be avoided in patients with end-stage renal disease (ESRD). NaHCO3 may serve as an alternative therapy for metabolic acidosis with less risk of enhancing Al absorption. 相似文献
6.
7.
8.
Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results 总被引:3,自引:0,他引:3
Mattrey RF; Strich G; Shelton RE; Gosink BB; Leopold GR; Lee T; Forsythe J 《Radiology》1987,163(2):339-343
In animals, perfluorochemicals (PFCs) are effective ultrasound (US) contrast agents that produce hepatic, splenic, and tumor enhancement. The use of Fluosol-DA 20%, an emulsion of perfluorodecalin and perfluorotripropylamine, was studied in nine non-critically ill patients with cancer who had liver lesions. US studies without Fluosol were compared with studies obtained 24, 48, and 72 hours after Fluosol infusion. Vital signs and extensive laboratory analyses are performed before and after Fluosol infusion. Liver metastases from colonic, pancreatic, and gastric carcinoma exhibited rim or diffuse enhancement after a Fluosol dose of 1.6 g/kg or greater. Fluosol produced echogenic enhancement of the liver and spleen relative to kidney at a dose of 2.4 g/kg, allowing the detection of nonenhancing lesions. In addition, Fluosol at a dose of 1.6 g/kg or greater allowed detection of lesions not seen before contrast medium was administered in three of the seven patients studied. There was a mild increase in the level of serum glutamic oxaloacetic transaminase in two patients, one given 2.4 and the other 3.2 g/kg of Fluosol. Mild and transient allergic reactions without change in vital signs were experienced by two patients. 相似文献
9.
10.
Coralline hydroxyapatite bone graft substitutes: preliminary report of radiographic evaluation 总被引:1,自引:0,他引:1
A new bone graft substitute made by conversion of the calcium carbonate exoskeleton of reef-building sea coral into hydroxyapatite has recently become clinically available. The normal radiographic appearance of two forms of this material is described. In the immediate postoperative period, the exoskeletal architecture of these implants is readily appreciated. With graft incorporation over the ensuing months, their intrinsic structure is gradually lost in association with poor marginal definition. Evolving radiographic findings reflect the biocompatible nature of these implants, which provides the potential for ingrowth of native bone with preservation of the coralline scaffold, resulting in enhanced biomechanical properties. 相似文献